Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Maze Therapeutics, Inc.NASDAQ: MAZE
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $153.62M, compared with $0 a year earlier.
Context
- Short-term investments amounted to 36.6% of total assets at the end of Q1 FY2026, up 36.6 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 152.67M USD
- Year-over-year change
- —
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 152.67M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Short-term investments amounts to 36.6% of total assets for MAZE, versus a peer median of 41.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.18B USD | +21.3% | +94.4% | 36.3% | |
| Sep 2026 | $348.28M USD | +142.5% | -16.1% | 41.1% | |
SEPNSepterna, Inc. | Sep 2026 | $311.48M USD | +101.8% | — | 50.3% |
| Mar 2026 | $206.87M USD | +13.0% | +92.0% | 41.0% | |
| Mar 2026 | $153.62M USD | — | — | 36.6% | |
BIOABioAge Labs, Inc. | Mar 2026 | $141.42M USD | +124.4% | — | 35.6% |
| Mar 2026 | $46.46M USD | +37.7% | +15.4% | 87.5% | |
| Dec 2025 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding MAZE) | — | +69.8% | +53.7% | 41.0% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.